ID   A549/TXL5
AC   CVCL_W192
DR   cancercelllines; CVCL_W192
DR   Wikidata; Q54607054
RX   CelloPub=CLPUB00006;
CC   Population: Caucasian.
CC   Doubling time: 74.7 hours (CelloPub=CLPUB00006).
CC   Selected for resistance to: ChEBI; CHEBI_45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 15
//
RX   CelloPub=CLPUB00006;
RA   Wang Z.-J., Li M., Zhao W.-C., Zhao G.-Q., Dong Z.-M.;
RT   "Establishment and characterization of lung adenocarcinoma cell lines
RT   with multidrug resistance.";
RL   Life Sci. J. 4:13-16(2007).
//